ArticleTransboundary and emerging diseases2026
A Novel Attenuated NADC30-Like PRRSV Vaccine Candidate Provides Cross-Protection Against Homologous and Heterologous Viral Challenge.
Article in Transboundary and emerging diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Novel Attenuated NADC30-Like PRRSV Vaccine Candidate Provides Cross-Protection Against Homologous and Heterologous Viral Challenge.Transboundary and emerging diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Porcine reproductive and respiratory syndrome (PRRS) virus (PRRSV) is one of the major pathogens threatening the global swine industry and causes enormous economic losses annually. Vaccination remains one of the most important strategies for the prevention and control of PRRSV infection. In this study, a novel genotype 2 NADC30-like PRRSV strain, designated AHFY, was isolated and characterized from eastern China. Phylogenetic analysis revealed that strain AHFY belonged to sublineage 1.8. An attenuated strain, AHFY-F140, was obtained through 140 serial passages in MARC-145 cells. Genomic sequence comparison between AHFY-F140 and the parental strain AHFY-F1 identified two discontinuous amino acid (aa) deletions in the nonstructural protein 2 (NSP2) gene, spanning residues 355-364 and 391-583, which were first detected at passage 90 and persisted through passage 140. The viral titer gradually increased with passaging, rising from 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.